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Abstract 
Objectives: We aimed to assess the evidence for the use of 8-isoprostane in exhaled 
breath condensate (EBC) as a biomarker in adult asthma.  Design: A systematic review 
and meta-analysis of EBC 8-isoprostane.  Methods: We searched a number of online 
databases (including PubMed, Embase and Scopus) in January 2016. We included studies 
of adult non-smokers with EBC collection and asthma diagnosis conducted according to 
recognised guidelines. We aimed to pool data using random effects meta-analysis and 
assess heterogeneity using I2.  Results: We included twenty studies, the findings from 
which were inconsistent. Seven studies (n = 329) reported 8-isoprostane levels in asthma 
to be significantly higher than that of control groups, whilst six studies (n = 403) did not. 
Only four studies were appropriate for inclusion in a random effects meta-analysis of mean 
difference. This found a statistically significant between-groups difference of 22pg/ml. 
Confidence in the result is limited by the small number of studies and by substantial 
statistical heterogeneity (I2 = 94).  Conclusion: The clinical value of EBC 8-isoprostane 
as a quantitative assessment of oxidative stress in asthma remains unclear due to 
variability in results and methodological heterogeneity. It is essential to develop a robust 
and standardised methodology if the use of EBC 8-isoprostane in asthma is to be properly 
evaluated. 
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Introduction  
With the ascendance of personalised medicine and recognition of the heterogeneity within 
asthma there has been a drive to develop non-invasive measures of disease activity. 
Collecting and analysing the condensate from exhaled breath (EBC) is one such method, 
studied since the early 1980’s (1). Several different commercial devices are available and 
this methodology has been adopted in a number of studies looking at an ever growing 
number of potential biomarkers.  
Oxidative stress is thought to play an important role in asthma, as both a causative factor 
and a result of inflammation (2, 3). It occurs where there is a failure of homeostasis - due 
either to an excess of reactive oxygen species (ROS) or to a lack of antioxidants - and can 
cause cellular damage, proinflammatory mediator release, mucous secretion, remodelling 
of extracellular matrix, smooth muscle contraction and bronchoconstriction (3-5).  
The reaction of ROS with other molecules is so rapid that their direct measurement is 
difficult; however, end products of ROS ‘attack’ are more stable and may be useful as 
surrogate markers for oxidative stress. 8-isoprostane is one such marker; specific to 
oxidative stress, stable, and measurable in EBC (6-8). Paediatric studies of EBC 8-
isoprostane have been the subject of a systematic review (9) which found the majority of 
studies reported a significant association between 8-isoprostane and asthma, however, as 
biomarker thresholds vary with age (10), there is a need to review the adult literature. 
We aimed to assess the evidence regarding the efficacy of EBC 8-isoprostane as a 
biomarker – its ability to identify disease, disease severity and response to treatment. We 
chose to conduct a comprehensive systematic review because this enables us to view the 
evidence as whole, and to identify common themes as well as inconsistencies that may 
only become apparent through evaluation of the entire dataset. 
Methods 
Study design 
The study protocol was registered with and is available from the International Prospective 
Register of Systematic Reviews (PROSPERO) (registration number CRD42016027312).  
The primary objective of the review was to assess the ability of 8-isoprostane to identify 
and distinguish between a) those with asthma and healthy controls b) levels of asthma 
severity, and c) response to treatment. A secondary objective was to determine possible 
thresholds appropriate to a diagnosis of asthma or classification of severity. 
Search Strategy 
A search strategy was developed using terms relating to asthma, exhaled breath 
condensate and 8-isoprostane (see appendix table 1).   
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Two reviewers (AMP & CJCB) screened titles and abstracts for inclusion, resolving 
discrepancies through discussion with a third reviewer (YKL). The screening and selection 
process is described in a PRISMA flow chart (see figure 1).  
Fig. 1 – PRISMA Diagram 
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Eligibility criteria 
Inclusion / exclusion criteria are described in table 1 below. 
 
Table 1 – Inclusion & Exclusion Criteria 
Inclusion criteria Exclusion criteria 
Abstract in English 
Primary data 
Quantitative data 
Diagnosis of asthma according to 
recognised guidelines 
EBC 8-isoprostane measured 
Human subjects 
Adult participants (aged 18+) 
Review articles 
Studies including paediatric patients 
Studies of occupational asthma 
Studies of current smokers  
In vitro studies 
Use of a custom EBC device with insufficient 
description or which fails to meet ATS/ERS 
guideline recommendations (11). 
Studies published as comment / letters will have 
a request for further information made; they will 
be excluded if further detail is not forthcoming. 
 
Studies were excluded if the EBC collection device failed to meet ATS/ERS construction 
guidelines (12) (or was described insufficiently to determine this), or if the method of 
asthma diagnosis failed to meet recognised guidelines or was incompletely described.  An 
exception to this was the use of nose-clips; although this was recommended, the 
guidelines state that there were no data underpinning this recommendation. A study by 
Vass et al (13) published since the guidelines found no significant difference between 
samples collected with or without nose-clips (although 8-isoprostane was not one of the 
mediators studied).  
During the initial screening process several conference abstracts were found. On 
contacting the authors it was confirmed that the results had not been published more fully 
elsewhere but insufficient information was forthcoming to determine suitability for 
inclusion. In order to avoid selective dissemination bias an analysis of these papers was 
included.  
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Data Extraction & Quality Assessment 
Data extraction and quality assessment was conducted by two reviewers independently 
(AMP and CJCB). Data were extracted directly into SPSS (14); papers were assessed for 
quality and risk of bias (15); and the overall strength of evidence was assessed (16, 17). 
Discrepancies between the two reviewers were resolved through discussion with a third 
(YKL). 
Statistical methods 
We aimed to produce a quantitative synthesis using methods appropriate to the data 
extracted and to assess statistical heterogeneity using the I2 statistic. We used Open-Meta 
Analyst to conduct a random effects meta-analysis of mean difference (between asthma 
and control groups) for those studies reporting continuous data with a mean and standard 
deviation (SD). Where the SD was not reported we calculated it from confidence intervals 
or standard error (except where data had been transformed). In studies with multiple 
arms we combined data. We were not able to include papers which presented their results 
as a median and range.  
 
Results 
We identified 1,045 papers through the database search and a further five through 
reference searches (see PRISMA diagram, appendix figure 1). This was reduced to 768 on 
removal of duplicates. Title and abstract screening resulted in 41 papers which was 
reduced to 20 after screening full texts. Study characteristics are summarised in table 2.  
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Table 2.  Study characteristics and results 
 
Author Publication 
type 
Country N = 
 
EBC device Method 
of 
analysis 
Study focus Severity of 
asthma 
population 
Significant 
difference 
between 
asthma & 
controls? 
Significant 
difference 
between 
asthma 
severities? 
Battaglia et al (2005) Journal Netherlands 31 EcoScreen ELISA Small airway 
function 
Mild - - 
Brussino et al (2010) Journal Italy 32 RTube ELISA Allergen 
challenge 
Mild P<0.001 - 
Carpagnano et al (2006) Journal Italy 26 EcoScreen ELISA + 
GC-MS 
GORD Mild persistent - - 
Fritscher et al (2012) Journal Canada 67 RTube LC-
MSMS 
COPD & asthma Mild persistent  NS - 
Gratziou et al (2008) Journal Greece 28 EcoScreen ELISA Seasonal allergic 
rhinitis & asthma 
Mild (previously 
untreated) 
P<0.05 - 
Head & Mickleborough 
(2013) 
Journal USA 7 EcoScreen LC-MS  Supplements Mild-to-
moderate 
- - 
Komakula et al (2007) Journal USA 114 RTube ELISA BMI Moderate-to-
severe 
NS - 
Kostikas et al (2002) Journal Greece 50 Custom 
device  
ELISA pH Mild + 
moderate 
- - 
Mastalerz et al (2011) Journal Poland 21 EcoScreen GC-MS Aspirin sensitivity Mild-to-
moderate 
- - 
Mastalerz et al (2015) 
 
Journal Poland 53 EcoScreen GC-MS Aspirin sensitivity Moderate - - 
Mickleborough et al 
(2013) 
Journal USA 20 EcoScreen ELISA Supplements Mild-to-
moderate 
- - 
Piotrowski et al (2011) Journal Poland 52 EcoScreen ELISA Asthma severity Severe + never 
treated 
NS  NS 
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Samitas et al (2009) Journal Greece 62 EcoScreen ELISA Asthma severity Mild + 
moderate + 
severe 
P<0.001 P < 0.01 
Shimizu et al (2007) 
 
Journal Japan 62 EcoScreen ELISA GORD Moderate P<0.05 - 
Sood et al (2013) 
 
Journal USA 14 RTube ELISA  Allergen Mild atopic NS - 
Zhao et al (2008) 
 
Journal Japan 64 EcoScreen ELISA GORD Mild P = 0.034 - 
 
Potentially eligible studies 
(conference abstracts) 
 
 
Gemicioglu et al (2014) Conference 
abstract 
Turkey 19 No info No info 
given 
Smokers & non-
smokers 
Newly diagnosed - - 
Holguin & Fitzpatrick 
(2009) 
Excerpt in 
review 
article 
USA 125 RTube No info 
given 
BMI Moderate-to-
severe 
NS - 
Sedlak et al (2013) Conference 
abstract 
Czech Republic 61 EcoScreen LC-MS Inflammatory 
phenotype 
Severe refractory  P<0.001 - 
Sedlak et al (2012) Conference 
abstract 
Czech Republic 20 No info LC-MS Oral steroids Difficult-to-
control 
P<0.001 - 
 
p<  = a significant relationship reported       ELISA = Enzyme-linked immunosorbent assay 
NS  = a non-significant relationship reported      GC-MS = Gas chromatography mass spectrometry 
 -    = not analysed or not-reported          LC-MS  = Liquid chromatography mass spectrometry 
N  = number of participants in asthma and healthy control groups eligible for inclusion          GORD = Gastro-oesophageal reflux disease
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QUALITY ASSESSMENT  
 
Results of the Quadas-2 quality assessment can be found in appendix table 3. It was not 
possible to assess the risk of bias arising from patient selection methods or from the 
conduction of the index test (EBC collection); in all but one paper description of patient 
sampling and/or recruitment methods was absent, and in only one paper was it clear 
whether the laboratory analysis of EBC was conducted by someone blinded to the 
participants’ asthma status.   
The time between reference and index standards was not clearly stated in five of the 
papers. The larger the interval the greater the risk of a change in condition between the 
two assessments and potential misclassification of asthma severity; we deemed asthma 
assessment within 1 week of EBC collection to be acceptable. Participant drop-out occurred 
in very few studies. 
Variability: Pre-analytical 
One study (Samitas et al (18)) coated the condenser surface of their EBC collection device 
in Tween-20 (a non-ionic surfactant) to reduce eicosanoid adherence. They report 8-
isoprostane concentrations which are towards the higher end of results within this review. 
The extent to which this was due to the use of Tween-20 is unclear; Sood et al (19) 
examined this method and found no significant difference in 8-isoprostane between 
samples collected with or without Tween. 
Three studies (Battaglia et al (20), Fritscher et al (21) and Sood et al (19)) undertook or 
cited 8-isoprostane recovery rates obtained from spiking tests; all were over 90%. Sood 
et al found that concentrating their samples by lyophilisation had no effect on recovery 
rates, whereas Battaglia et al found lower rates when they used an immunoaffinity sorbent 
and lyophilisation. 
Kostikas et al (22) cooled their condensing surface to minus 10oC whereas other studies 
used minus 20oC. We included this study as it does not contravene ATS/ERS 
recommendations and evidence on the effect of temperature on EBC 8-isoprostane 
collection is conflicting (23-25).  
Not mentioned in the ATS/ERS guidelines but specified by Cayman in their enzyme-linked 
immunosorbent assay (ELISA) information (26) is the use of an anti-oxidant - butylated 
hydroxytoluene (BHT) - for EBC samples which are being frozen and stored for later 
analysis. This is to prevent further (in vitro) oxidative formation of 8-isoprostane. The 
majority of studies using ELISA kits stored their samples for later analysis but none 
reported the use of BHT.  
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Relatively few studies reported the length of time samples were stored for but Samitas et 
al evaluated the stability of 8-isoprostane at minus 80oC and found no significant difference 
in samples tested at one, four and eight weeks (although an upward trend could be noted).  
Variability: Analytical 
For their ELISA, Cayman cited a sensitivity of 3pg/ml and inter-assay variation rates of 
10-24% however this validation was not undertaken in EBC. Sood et al (19) found the 
intra-assay CV in EBC to be 37.7% compared to 6% in buffer diluent. They concluded that 
interference from the EBC matrix was possible; the extent to which this might be a 
confounder in other studies is unclear as Sood et al’s analysis was conducted on a 
lyophilised, concentrated EBC sample. The majority of studies in this review cite intra-
assay and inter-assay CV <10%.  
Several studies utilised mass spectrometry techniques as their method of analysis – GCMS 
and LC-MS/MS methods offer improved sensitivity and selectivity over immunoassays, 
hence they are often regarded as the superior method for measurement of isoprostanes 
(27-29). Fritscher et al (21) report the limit of detection with LC-MS to be 0.05-0.1pg; 
while Mastalerz et al (30) report that of GC-MS to be between 0.17 and 0.89pg/ml. The 
results found by studies using mass-spectrometry frequently fell below the lower detection 
limit of immunoassays. Two papers compared the results produced by ELISA methods with 
a) GC-MS (Carpagnano et al) and b) radioimmunoassay (Sood et al). Sood et al report 
discordance between methods while Carpagnano do not.  
The absence of prime certified standard reference materials (SRM) produced by accredited 
bodies (such as NIST) for the production of calibration curves is a further source of 
potential inaccuracy and inter-laboratory variation. 
Grade Assessment 
A GRADE assessment was completed (using GradePro GDT (31)) for the twelve studies 
reporting on both asthma and control groups (see appendix table 4). The strength of the 
evidence pertaining to the differentiation of disease status was judged to be very low due 
to the inconsistency and imprecision of results. 
Summary 
For the majority of included papers there are no concerns over applicability to the review 
question but the risk of bias in the studies is largely unclear and there are unresolved 
methodological questions. Overall assessment of the evidence grade is very low.  
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QUANTITATIVE SYNTHESIS  
Prediction of asthma attack or treatment response 
There were no studies examining the strength of association between 8-isoprostane 
concentration and frequency of asthma attack, nor studies examining the ability of 8-
isoprostane to predict the risk of attack or response to treatment.  
Differentiation of disease status  
There was a large degree of clinical heterogeneity; studies examined different asthma 
phenotypes and severities, and utilised different interventions (including provocation tests 
and treatments). Given the broad study question we were addressing we considered the 
studies sufficiently homogenous for meta-analysis despite these differences.  
Using Open Meta Analyst (32) we conducted a random effects meta-analysis of mean 
difference between groups (see figure 2). The estimated mean difference was +21.62 
pg/ml in those with asthma (standard error 5.21). The p-value of <0.001 suggests 
statistical significance, and the lower bound of the meta-analytical point estimate - 
11.4pg/ml – is above the detection limit for the ELISA (2.8 to 7pg/ml). However, the I2 
test result - 94 - suggests a considerable degree of statistical heterogeneity, and the 
estimated mean difference (21.62pg/ml) should be viewed in light of the overall range of 
averages for EBC 8-isoprostane which varied from 0.25pg/ml to 78.10pg/ml.  
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Figure 2 - Random Effects Meta-Analysis of Mean Between-Group Difference  
(asthma vs controls) 
 
Study weights: Kostikas 25%, Samitas 23%, Shimizu 25%, Zhao 27%. 
 
_________________________________________________________________________________________________________________________ 
 
1 Zhao et al (33) cited a median and IQR but also gave a mean. There was little difference between the mean and median (16 vs 16.2 respectively); we therefore 
calculated SD from the IQR and included this study in the meta-analysis. 
(pg/ml) 
1 
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QUALITATIVE SYNTHESIS  
Ten papers (n = 419) reported average 8-isoprostane levels to be higher in asthma than 
in healthy controls, while five papers (n = 389) reported averages to be the same or higher 
in controls.   
Of the ten studies reporting higher concentrations in asthma, only seven (n=329) reported 
the difference to be statistically significant. However, of the three which were excluded, 
two (22, 34) simply omitted to report the significance level, while the third study – Sood 
et al (19) - was not powered to detect a between-group difference in 8-isoprostane 
concentration. 
With the exclusion of conference abstracts, five papers (n=248) report a significant 
difference, and five papers (n=278) report either no significant difference or higher 
concentrations amongst controls.  All papers scored similarly in their quality assessment. 
A full list of results can be found in appendix table 5. 
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Results from those papers reporting a median (figure 3) and those reporting a mean 
(figure 4) are displayed below. Even when looking only at those studies reporting a 
significant between-groups difference, there is a considerable overlap of results between 
studies - the range of values for controls in one study being similar to those for asthma in 
another. This degree of statistical heterogeneity precludes the determination of threshold 
values. 
Figure 3 – Median 8-isoprostane and Range: Asthma groups versus controls 
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Figure 4 – Mean 8-isoprostane and Standard Deviation: Asthma groups versus 
controls 
 
 
 
There was a large degree of overlap in 8-isoprostane concentration between severities of 
asthma. This may be attributable to between-study methodological differences, however, 
three studies (18, 21, 35) made within-study comparisons of severity. Samitas et al (18) 
report a significant difference between the severe and milder asthma groups, whereas 
Piotrowski et al (35) report a small, non-significant difference (0.87 pg/ml). Kostikas et al 
(36) report a difference of 15 pg/ml but do not comment on its statistical significance. 
Both Brussino et al (37) and Sood et al (19) investigated the effect of allergen challenge 
on EBC 8-isoprostane concentration. Brussino et al reported a statistically significant 
increase while Sood et al reported no such change.  
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Gratziou (38) studied patients with seasonal allergic rhinitis and concurrent asthma, 
reporting significantly higher levels of 8-isoprostane during pollen season, and a significant 
decrease after treatment with nasal corticosteroids. Mastalerz et al (30, 39) conducted a 
pair of studies in which patients with aspirin intolerant asthma (AIA) or aspirin exacerbated 
respiratory disease (AERD) were subjected to an aspirin challenge; they found no 
significant difference in 8-isoprostane after challenge. 
Baseline measures of pulmonary function (spirometry) were commonly reported in order 
to characterise study populations; their relation to EBC 8-isoprostane was less commonly 
examined. Eight studies conducted such an analysis, of which only two reported a 
significant (negative) correlation. Similarly, baseline blood eosinophil count was reported 
by five papers but analysed in relation to 8-isoprostane by only one (reporting no 
correlation). FeNO was measured by six studies; four assessed the degree of correlation 
with EBC 8-isoprostane only one of which yielded a statistically significant (positive) 
association. Two papers undertook sputum analysis; one reported on the relationship with 
EBC 8-isoprostane - no significant association was found.  
SUBGROUP ANALYSIS 
Methodological heterogeneity has been suggested as one of the factors inhibiting clinical 
use of EBC (12). Those papers included in the meta-analysis all used ELISA as their method 
of analysis but represent a mixture of asthma severities and EBC collection devices. A sub-
group analysis of EBC collection and analytical methods was used as a means of exploring 
this heterogeneity.  
Five of the seven studies using the EcoScreen reported a positive difference between 
asthma and control groups; four were statistically significant, the fifth was not reported 
upon. Of the four studies using the RTube, two reported a positive difference between 
groups of which one was statistically significant. The condensing surface of the RTube is 
polypropylene while on the EcoScreen it is teflon. Several papers have looked at the 
possible impact of device and condensing surface upon EBC results (23-25, 40-44). Czebe 
et al (24) compared the RTube and EcoScreen and concluded that both temperature and 
condenser surface had an impact on biomarker levels. Soyer et al (23) found similar results 
although neither study examined 8-isoprostane. Rosias et al (25) did study 8-isoprostane 
and concluded that condenser surface did have an effect but that there was no difference 
between polypropylene and teflon. Moreover they concluded that temperature difference 
between the two did not appear to have a significant effect on 8-isoprostane collection. 
Based on current studies of methodology we cannot be certain that choice of device 
explains any of the heterogeneity in the results. 
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Regarding analytic method, if the outlier generated by the inclusion of conference abstracts 
(Sedlak et al (45)) is excluded, the results from mass spectrometry exhibit a smaller range 
and are considerably lower than the majority of results from ELISA. However, Carpagnano 
et al (34) – the only study to confirm their ELISA results using gas chromatograph-mass 
spectrometry - report no discrepancy between the two measures; this is in line with 
previous studies (46). That analytical method is responsible for a degree of heterogeneity 
in the results is plausible but cannot be stated with certainty. 
The inclusion of papers studying mild or intermittent asthma - in which there may be little 
or no oxidative stress – might explain the lack of consistently observed difference between 
asthma and control groups.  
A sub-group analysis comparing moderate-to-severe asthma with controls was conducted 
to explore this possibility. Results were inconclusive; of the eight included papers (18, 22, 
35, 45, 47-50) five reported a between-groups difference (four of which were statistically 
significant) while three reported no difference (see appendix table 6). 
Discussion 
This review highlights a lack of comparability between studies, as well as evidence gaps 
which create difficulties in determining 8-isoprostane thresholds for diagnosis or severity 
classification of asthma. The clinical value of EBC 8-isoprostane as a quantitative 
assessment of oxidative stress in asthma remains unclear due to variability in results and 
inadequate standardization. 
The previously published paediatric review (9) reported more consistent findings - five of 
the six identified studies found a significant difference between asthma and healthy control 
groups. However, the studies exhibited a similarly large degree of variance in their results 
(ranging between 4.2 – 56.4pg/ml for asthma and 2.6 – 34.2pg/ml for control groups). 
The ATS / ERS taskforce of 2005 (11) was set-up to address variability in EBC results and 
lack of standardisation in methods. They suggested two likely contributors to variability - 
varying EBC dilution levels and biomarkers being at the lower end of assay sensitivity. 
That there exists a large degree of variance in 8-isoprostane concentration levels even 
where studies have used the same EBC collection method would support these assertions.  
Ahmadzai et al in 2013 (51) discuss three possible methods of calculating a dilution factor, 
none of which has established itself as a gold standard and none of which were used in 
the studies comprising this review. Only one study (30) used a dilution factor, giving their 
results in both pg/ml and parts per million of palmitic acid. It remains to be seen whether 
this improves reproducibility.  
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It has been suggested that lyophilisation may be useful for reducing variability by 
concentrating samples thereby raising biomarkers away from the lower end of assay 
sensitivity. There are a lack of studies examining the reliability and reproducibility of this 
method (51). Unfortunately the only studies in this review to have used this approach 
(Battaglia et al (20) and Sood et al (19)) concentrated their samples to differing levels 
(threefold and fourteenfold respectively). Furthermore, Sood et al reported an intra-assay 
CV of 37.7% and an inter-day CV of 71.6% when using this method.  
The validity of any assessment of diagnostic test accuracy rests upon the accuracy of the 
reference standard to which it is compared; we included studies where diagnosis was 
conducted according to recognised guidelines.  
A large number of exclusions were due to lack of diagnostic clarity; many undertook 
spirometry as a study measure rather than a diagnostic assessment and - unless reviewed 
by a physician and judged against a clearly described standard - can’t be accepted as 
diagnostic confirmation. Furthermore, guidelines stress the importance of variable airflow 
obstruction to diagnosis; this cannot be assessed by a single spirometry measurement 
thereby complicating the process for any study wishing to have a rigorous diagnosis as 
the basis for inclusion.  
Of concern were studies where it was neither explicitly stated that smokers were excluded, 
nor was smoking status featured in the participant description. There were six studies in 
which this occurred and over which there must be some concern that data might include 
that from smoking participants. This would be a potential confounder; there is evidence 
that EBC 8-isoprostane is significantly higher in smokers compared to healthy controls 
(52) and may increase in an acute smoking response (53).  
Another potential confounder is the effect of food and drink; sixteen of the studies did not 
mention fasting prior to tests. The ATS/ERS guidelines (12) state that eating and drinking 
do not affect the non-volatile components of EBC as far as is known, but Ahmadzai (51) 
point out that food & drink may elevate levels of oxidants in body fluids and has the 
potential to influence oxidant concentrations in EBC (although they identify no studies 
describing any such effect on 8-isoprostane). The extent to which this might constitute a 
confounder is unknown.  
Several authors confirmed they were unable to measure 8-isoprostane in a majority of 
their samples (54-56). Of those studies in this review which reported undetectable samples 
the percentage ranged from 16% (Komakula et al) to 50% (Piotrowski et al). Not all papers 
made clear the cause of missing data (whether an inability to obtain EBC samples or an 
inability to detect 8-isoprostane) nor how this was handled in the analysis. Gratziou et al 
(38) gave non-detectable levels of 8-isoprostane a value of 3.9pg/ml (the lower limit of 
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assay detection) while Sood et al ascribed undetectable levels a value half the lower 
detection limit; neither state how many cases this applied to. If these samples came 
predominantly from healthy controls, raising them might obfuscate any difference between 
asthma and controls.  
The absence of oxidative stress is a potential explanation of inability to detect 8-
isoprostane. This might be the case for studies of mild or intermittent asthma. The use of 
provocation tests or the study of moderate-to-severe asthma is one potential approach to 
this problem but the results of such studies were no less conflicted. 
Although not one of our primary objectives we examined those factors for which an 
association with 8-isoprostane was reported. The majority of studies which assessed GORD 
and BMI reported a significant association with 8-isoprostane. It is possible that these are 
important confounders which may need to be controlled for in future studies. 
Limitations 
By employing rigorous inclusion criteria for asthma diagnosis and EBC methodology 
several ‘key’ papers were excluded, including that of Montuschi et al (46) frequently cited 
by others as justification for their methodology. We believe these exclusions were justified; 
the use of rigorous inclusion criteria are crucial for a review of diagnostic test accuracy.  
Inability to assess the risk of bias in key domains of the QUADAS-2 quality assessment 
tool makes any conclusions from this review necessarily tentative. Furthermore, we were 
able to conduct meta-analysis of only four studies due to the frequent use of median, 
range, and log-transformed data.  
The increasing ability to examine several biomarkers - for example Sedlak et al (45, 47) 
– creates a risk that non-significant findings may go unreported unless high reporting 
standards are adhered to. Hussain et al mention EBC 8-isoprostane in the methods section 
of a conference abstract (57) but not in the results, nor anywhere in the full published 
paper (58); suggesting that 8-isoprostane was either undetectable or the results were 
non-significant. Although these may constitute a publication bias, the under-
representation of negative findings makes the lack of positive findings in this review more 
robust.  
Conclusion 
There is a trend towards higher EBC 8-isoprostane concentrations in subjects with asthma 
compared to controls. Twice as many studies reported higher levels amongst those with 
asthma than did not. However the strength of this evidence is weak and the number of 
studies reporting a significant difference was the same as that reporting none. A random 
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effects meta-analysis found a significant difference between groups however its rigour is 
compromised by the small number of studies and substantial statistical heterogeneity.  
Concentrating EBC samples may address some of the variability and difficulty arising from 
the use of ELISA. However, the central issue of calculating EBC dilution cuts across 
analytical methods and a gold standard is still to be determined. It will be essential to 
develop accurate, reliable and standardised methods of both EBC collection and 8-
isoprostane analysis if its use as a biomarker in asthma is to be properly evaluated. 
 
 
Appendix 
 
Table 1 - Search Terms 
 
Terms relating to the condition of interest -
asthma  
Asthma* OR “Bronch* hyperreactivity” 
 
Terms relating to the collection method -
exhaled breath condensate. 
“Exhaled breath condensate” OR “Breath test*” 
OR “Lung function test*” OR “Expired air” 
Terms relating to the biomarker of interest -  
8-isoprostane 
*isoprostane* OR Dinoprost* OR *prost* OR 
“Lipid peroxid*” OR *prostaglandin* 
 
Master search string 
(adapted for use in individual databases as 
required) 
 
(Asthma* OR “Bronch* hyperreactivity”) AND  
(“Exhaled breath condensate” OR “Breath test*” 
OR “Lung function test*” OR “Expired air”) AND 
(*isoprostane* OR Dinoprost* OR *prost* OR 
“Lipid peroxid*” OR *prostaglandin*) 
 
 
The strategy was modified as required for individual databases and the implemented in 
the following online databases: Cochrane, Embase, PubMed, Lilacs, Scopus, 
ClinicalTrials.gov, Open Grey and ProQuest. 
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Table 2 - Data Extraction Table 
 
Data extraction table 
Study ID number, Authors, Year of publication, Country of study, Source / type of 
publication 
 
Study design, Diagnostic criteria used, Time horizon,  
 
Sample size (total), number in control group, number in asthma group 
 
Average age in asthma group, Percentage female 
 
Average age of controls, Percentage female 
 
Character of asthma group (severity ) 
 
Atopic status, Ethnicity, Intervention (e.g. allergen challenge, steroid therapy),  
 
EBC collection Device, Methodological omissions, Method of EBC analysis, Units 
used for 8-isoprostane 
 
Average 8-isoprostane in control group (mean or median), Baseline 8-isoprostane 
in asthma group (mean or median) 
 
Average 8-isoprostane after any intervention, average 8-isoprostane in severity 
groups (e.g. mild, moderate, severe), average 8-isoprostane in steroid treated 
group (baseline & post-treatment), average 8-isoprostane in steroid naïve patients 
with asthma. 
 
8-isoprostane correlations with - FeNO, CO, pulmonary function (e.g.  FEV1 or FVC 
(% predicted), sputum 8-isoprostane, plasma 8-isoprostane, serum inflammatory 
markers (e.g. ESR, CRP). 
 
8-isoprostane correlations with -  age, BMI, Cys-LTs, PGE2, results of methacholine 
provocation test, interleukins (e.g. IL4, IL6), pH, sputum cell count, LTB4, urinary 
markers,  any other associations reported on (present or absent, positive or 
negative)  
 
Reported difference between controls and asthmatics; Significance of difference. 
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. 
.. 
Table 3 - QUADAS-2 Assessment 
 
Study RISK OF BIAS APPLICABILITY CONCERNS 
PATIENT 
SELECTION 
INDEX 
TEST 
REFERENCE 
STANDARD 
FLOW AND 
TIMING 
PATIENT 
SELECTION 
INDEX 
TEST 
REFERENCE 
STANDARD 
1. Battaglia 2005   ?   ? ☺  ☺ ☺ ☺ 
2. Brussino 2010   ?   ? ☺ ☺ ☺ ☺ ☺ 
3. Carpagnano 2006 ☺   ? ☺ ☺ ☺ ☺ ☺ 
4. Fritscher 2012   ?   ? ☺   ? ☺ ☺ ☺ 
5. Gratziou 2008        ?   ? ☺ ☺ ☺ ☺ ☺ 
6. Head 2013   ?   ? ☺    ? ☺ ☺ 
7. Komakula 2007   ?   ? ☺ ☺ ☺ ☺ ☺ 
8. Kostikas 2002   ?   ? ☺ ☺ ☺ ☺ ☺ 
9. Mastalerz 2011   ?   ? ☺ ☺ ☺ ☺ ☺ 
10. Mastalerz 2015   ?   ? ☺ ☺   ? ☺ ☺ 
11. Mickelborough 2013   ?   ? ☺   ?   ? ☺ ☺ 
12. Piotrowski 2011   ?   ? ☺ ☺ ☺ ☺ ☺ 
13. Samitas 2009   ?   ? ☺ ☺   ? ☺ ☺ 
14. Shimizu 2007   ?   ? ☺   ? ☺ ☺ ☺ 
15. Sood 2013   ? ☺ ☺   ? ☺ ☺ ☺ 
16. Zhao 2008   ?   ? ☺   ? ☺ ☺ ☺ 
 
Potentially eligible studies  
(conference abstracts) 
a. Gemicioglu 2014  [conf. abstract]   ?   ? ☺ ☺ ☺   ? ☺ 
b. Holguin 2009        [review excerpt]   ?   ?   ?   ? ☺   ?   ? 
c. Sedlak 2013        [conf. abstract]   ?   ?   ?   ?   ? ☺   ? 
d. Sedlak 2012        [conf. abstract]   ?   ?   ?   ?   ?   ?   ? 
 
 
☺ = low risk / low level of concern regarding applicability  
  ? = unclear risk / unclear level of concern regarding applicability 
 = high risk / high level of concern regarding applicability 
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Table 4 – GRADE Evidence Profile 
 
Setting: Adult non-smokers in any clinical setting.  
Bibliography: Battaglia, Hertog, Timmers et al (2005); Brussino, Badiu, Sciascia et al (2010); Carpagnano, Resta, Ventura et al (2006); Fritscher, Post, Rodrigues et al (2012); 
Gratziou, Rovina, Makris et al (2008); Komakula, Khatri, Mermis et al (2007); Kostikas, Papatheodorou, Ganas (2002); Piotrowski, Majewski, Marczak et al (2011); Samitas, 
Chorianopoulos, et al (2009); Shimizu, Dobashi, Zhao et al (2007); Sood, Qualls, Seagrave et al (2013); Zhao, Shimizu, Dobashi et al (2008).  
Quality assessment 
Impact  Quality Importance 
№ of 
studies 
Study design 
Risk of 
bias 
Inconsistency Indirectness Imprecision Other considerations 
Is exhaled breath condensate 8-isoprostane capable of differentiating between healthy controls and those with asthma? 
12  Mixture of 
observational 
and 
experimental 
studies  
Not 
serious  
Very serious 1 Not serious  Very 
serious 2 
Publication bias strongly 
suspected; 
all plausible residual confounding 
would reduce the demonstrated 
effect 3 
Cases (asthma) 353; controls 229.  ⨁◯◯◯ 
VERY LOW  
CRITICAL  
1. Significant unexplained variability in results; I-squared test for statistical heterogeneity = 94 
2. Large variance in study data   
3. Probable publication bias 
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is 
substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
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Table 5 - Study Results: Averages and Variance  
Author   Average EBC 8-isoprostane 
level 
 Units  
(measure of 
central tendency) 
Measure of 
variance 
Asthma 
(variance) 
 
Control 
(variance) 
Battaglia, Hertog, 
Timmers et al 
pg/ml 
(median) 
Range 2.10 
(1.6 - 2.7)  
3.6 
(2.9 - 7.6) 
Brussino, Badiu, Sciascia 
et al* 
pg/ml 
(geometrical mean) 
95% confidence 
interval 
21.56 
(19.92 - 23.35) 
16.43 
(15.50 - 17.41) 
Carpagnano, Resta, 
Ventura et al 
pg/ml 
(median) 
Range 17.90 
(8.9 - 23.8) 
6.9 
(5.6 – 9.7) 
Fritscher, Post, Rodrigues 
et al 
pg/ml 
(median) 
Range 0.60 
(0.4 - 2.0) 
0.9 
(0.2 - 1.7) 
Gratziou, Rovina, Makris 
et al 
pg/ml 
(median) 
Interquartile range 39.0 
(4.0 - 125) 
18.5 
(4 - 37) 
Head & Mickleborough pg/µl 
(mean) 
Standard error 3.08 
(+/- 1.5) 
_ 
Komakula, Khatri, Mermis 
et al* 
pg/ml 
(mean) 
95% CI 11.0 
(9.6 - 12.4) 
11.0 
(8.0 – 13.8) 
Kostikas, Papatheodorou, 
Ganas  
pg/ml 
(mean) 
Standard deviation 33.0 
(11) 
20.0 
(7) 
Mastalerz, Sanak, Kumik 
et al 
pg/ml 
(mean) 
Standard deviation 0.25 
(+/- 0.12) 
_ 
Mastalerz, Januszek, 
Kaszuba et al 
     AERD  
        & 
      ATA 
(two asthma groups 
within study) 
 
pg/ml 
(median) 
 
 
Interquartile range 
 
0.28 
(0.19 - 0.49) 
 
 
0.54 
(0.35 – 1.65) 
_ 
 
 
 
_ 
Mickleborough, Vaughn, 
Shei et al 
pg/ml 
(mean) 
Standard deviation 46.40 
(+/- 15.1) 
_ 
Piotrowski, Majewski, 
Marczak et al 
    Severe asthma 
              &  
Never treated asthma 
(two groups within study) 
pg/ml 
(median) 
Interquartile range  
3.8  
(2.5 – 10.73) 
 
4.67 
(2.5 – 27.92) 
 
 
6.93 
(2.5 - 12.98) 
 
 
Samitas, Chorianopoulos, 
et al  
pg/ml 
(mean) 
Standard error 59.30 
(+/- 4) 
16.4 
(+/- 1.6) 
Shimizu, Dobashi, Zhao et 
al 
pg/ml 
(mean) 
Standard error 27.70 
(+/- 2.3) 
6.6 
(+/- 1.2) 
Sood, Qualls, Seagrave et 
al* 
pg/ml 
(mean) 
Standard deviation 2.50 
(+/- 0.99) 
1.54 
(+/- 1.39) 
Zhao, Shimizu, Dobashi et 
al 
pg/ml 
(median)   
Interquartile range 16.20 
(11.7 – 19.1) 
3.5 
(2.6 – 7.9) 
 
* Log transformed data 
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Table 6 – Sub-Group Analysis: Moderate or Severe asthma  
 
 8-isoprostane concentration levels 
 Asthma > controls Controls > asthma 
All papers 5 studies 
(n = 253) 
3 studies 
(n = 273) 
Conference 
abstracts removed 
3 studies 
(n=174) 
2 studies 
(n =166) 
 
 
 
 
 
 
 
Potentially eligible studies 
(conference abstracts) 
Gemicioglu, Duman, 
Akdeniz et al 
No units given 
(mean) 
Standard deviation 135.72 
(+/- 38.85) 
 
Holguin & Fitzpatrick 
 
pg/ml 
(mean) 
95% confidence 
interval 
Unable to 
extract data 
_ 
Sedlak, Cap, Kacer et al No units given 
(?) 
No measure of 
variance given 
Result not 
directly cited 
_ 
Sedlak, Cap, Kacer et al pg/ml 
(?) 
No measure of 
variance given 
78.10 
 
_ 
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